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Abstract: The copper-catalyzed ring opening of chiral pool-derived 1,1'-diBoc-2,2'-biaziridine with 
Grignard reagents affords enantiopure 2-imidazolidinones in a desymmetrizing, cascade process 
involving the Boc protecting group. This divergent strategy provides reaction-ready, N-differentiated 
products and allows two C−C bond constructions concurrent to imidazolidinone formation. A variety 
of alkyl, cyclic and aryl Grignard reagents are tolerated in reasonable to good yields. 
2-Imidazolidinones are important heterocycles represented in bioactive compounds1 and 
peptidomimetics,2 as well as chiral ligands3 and auxiliaries4 in stereoselective synthesis (e.g., 1−4, 
Figure 1). Additionally, these five-membered cyclic ureas are precursors to other useful compound 
classes including vicinal diamines,5 cyclic guanidines6 and imidazolidinethiones.7 Although the 
traditional route to this heterocycle involves treatment of a vicinal diamine with an electrophilic 
carbonyl source,8 an abundance of alternate methods are now available which avoid the requirement for 
pre-synthesized diamines, offering greater product diversity in modular fashion.9 Despite these 
advances however, there remains comparatively few general methods which allow access to 4- and/or 
5-substituted 2-imidazolidinones with control of absolute stereochemistry.10 
 
 
Figure 1. Exemplary 2-imidazolidinones. 
Previously in our laboratory, as an intermediary step towards the synthesis of 2,2'-biindoline, we 
attempted the ring opening of tartaric acid-derived biaziridine 5 with a Grignard reagent, affording an 
imidazolidinone 6a as the major product arising from an unforeseen participation of the Boc protecting 
group (Scheme 1).11 Although 5 is an easily synthesized,12 bench-stable solid, its reactivity has 
remained unexplored beyond this example, thus we were inspired to further investigate the ring 
opening of 5 by Grignard reagents. As well as harboring the potential to prepare enantiopure 2-
imidazolidinones 6 in a divergent manner, this approach would allow direct access to reaction-ready, 
N-differentiated products, thus presenting downstream opportunities for sequential, asymmetric N-
functionalization.13 Furthermore, this method would constitute a useful addition to the limited existing 
synthetic strategies to enantioenriched trans-4,5-disubstituted imidazolidinones, which are specific to 
vinyl-derivatives14 or require multistep routes from amino acids15 or 1,3-dihydro-2-imidazolone.16 
 
Scheme 1. Proposed Synthesis of 2-Imidazolidinones 
 
We began this investigation by examining the effect of reaction parameters on the product ratio, in the 
search for conditions favoring imidazolidinone formation (Table 1). We were not concerned with 
pursuing a separate optimization of 7 in this study, as we have recently shown that the analogous tosyl-
biaziridine cleanly provides vicinal diamines of this type upon ring opening.17 For convenience, we 
selected commercially available i-PrMgCl as the model Grignard reagent. Our initial experiment was 
performed under similar conditions to reported previously,11,17 affording a mixture of the desired 
heterocycle 6b and vicinal diamine 7b in a 25:75 ratio (entry 1). Immediately, we noted a clear 
dependency of the product ratio on the Grignard reagent, given the reversal in major product from the 
previous reaction (see Scheme 1).  
 
  











1 4.0 15 0.10 25:75 
2 4.0 5 0.10 21:79 
3 4.0 0 0.10 - 
4 4.0 15   0.025 34:66 
5 2.4 15   0.025 55:45c 
6 2.4 15   0.025 56:44d 
7  2.4e 15   0.025 - 
a Reactions performed by pre-mixing 5 and CuBr·SMe2 in THF at −40 °C, adding i-PrMgCl and allowing the cooling bath to 
warm to rt over 16 h. b Determined by 1H NMR analysis of the crude mixture. c Isolated yields of 6b and 7b were 48% and 
26%, respectively. d Reaction time was 96 h. e i-PrMgCl added dropwise over 2 h to the reaction mixture at −20 °C. 
 
Undeterred by this result, we examined variations in the quantity of the catalyst: a reduction to 5 mol % 
gave a similar outcome (Table 1, entry 2), while omitting the copper salt completely resulted in neither 
product being observed (entry 3). Encouragingly, when the starting concentration of 5 was reduced, the 
ratio of 6b:7b was increased favorably (entry 4 versus entry 1). Maintaining this concentration and 
removing the excess Grignard reagent18 provided a further advantage, enabling 6b to emerge as the 
major product in 48% isolated yield (entry 5), along with 7b obtained in 26% yield, which was easily 
separated from 6b by flash chromatography due to its significantly lower polarity on silica gel. 
Subsequent experiments proved unsuccessful in further optimizing the outcome; increasing the reaction 
time (prior to NH4Cl quench) had a negligible effect (entry 6), while performing slow addition of the 
Grignard reagent at −20 °C returned mostly unreacted 5 (entry 7).19 
 
Although the yield of 6b was affected by the persistent formation of 7b, we remained optimistic that 
screening a variety of Grignard reagents would provide more favorable results, given the apparent 
dependency of the product ratio on the Grignard reagent. Therefore, we proceeded to examine the 
scope of the process under the newly established conditions (Table 2). A range of structurally and 
electronically diverse Grignard reagents such as cyclic, primary alkyl and functionalized benzylic and 
aryl carbanions, including ortho-substituted substrates, were found to be accommodated, affording the 
desired imidazolidinones 6a−6p in modest to good yields (37−84%). With the majority of Grignard 
reagents examined, the yield of 6 was notably lower than would be expected based on the product ratio, 
indicating biaziridine decomposition as a competing reaction pathway. The products were purified by 
silica gel flash chromatography and were observed to be stable to these conditions. 
 
Similarly to the isopropyl test substrate, clean C−C bond formation took place with the cyclohexyl 
Grignard reagent, but equimolar amounts of 6c and 7c were formed, resulting in a 46% yield of 6c 
(Table 2). Notably, all other Grignard reagents surveyed provided higher ratios of 6:7 than observed 
with the secondary carbanions (isopropyl and cyclohexyl). Primary alkyl (non-methyl) and aryl 
Grignard reagents were particularly good performers in this regard, providing molar ratios of 6:7 in 
excess of 90:10 in all cases. With aryl and vinyl Grignard reagents, up to 3.6 equiv of the carbanion 
was required for complete consumption of 5, although not at the expense of the product ratio.  
 
The method was revealed to be somewhat sensitive to inductive effects: the electron-rich 2-
methoxyphenyl Grignard reagent furnished 6l in 80% yield (Table 2), whereas the electron-deficient 3-
chloro derivative provided 6p in a reduced 37% yield. In the latter case, a number of unidentified side 
products were observed. The 2-bromophenyl Grignard reagent was required in four-fold excess for 
complete consumption of 5, presumably due to nucleophile loss via decomposition to benzyne.20 Under 
these conditions, 6a was obtained in 60% yield, with, at most, a trace of 7a formed, representing a 
significant improvement to our original lead result (Scheme 1). Unsuccessful substrates under the 
standard conditions included tert-butyl, ethynyl and 2-thienyl Grignard reagents (products not shown). 
In these cases, unreacted 5 was the predominant component in the crude mixture after work-up. 
 
NMR analysis of the products revealed some notable general characteristics. H4 was observed in all 
cases as an apparent triplet (δ 3.14−3.63 ppm, J = 5.7−7.4 Hz), while H5 routinely resonated further 
downfield as a doublet (δ 3.73−4.40 ppm, J = 7.8−10.8 Hz). These multiplicities were attributed to 
vicinal coupling with their adjacent methylene protons (HA and HB), as no correlations between H4 
and H5 were observed by gCOSY analysis. The diastereotopic methylene protons at HA, as well as 
HB, were fully resolved as two distinct doublets of doublets for some compounds derived from aryl 
Grignard reagents (e.g., 6k, 6n). In regards to the 13C NMR spectra, several products bearing pendant 
aryl moieties exhibited up to two doubly degenerate signals (ArC’s), likely as a consequence of the 
pseudo C2-symmetric nature of the compounds. 
 





RMgX (2.4 3.6 equiv)
CuBr SMe2 (cat)
THF, 40 C rt, 16 h





























































6m: 60% (>90:10) 6n: 70% (>90:10)
6l: [ ]D = 18.0




a Reactions performed with 0.14 mmol of 5 and 10−15 mol % CuBr·SMe2 (wrt RMgX). 
b The product ratio was determined 
by 1H NMR analysis of the crude reaction mixture and 6 was isolated by flash chromatography. c Product ratio unable to be 
determined with more precision due to multiple side products. d 4 equiv RMgX used, some unreacted 5 was returned. e 8 
equiv RMgX used. f ent-5 used. Red-colored bonds highlight new C−C bond formation. 
 
As anticipated, all evidence pertaining to the stereochemical purity of the products pointed conclusively 
to a complete chirality transfer from the biaziridine. The absence of diastereoisomers in the NMR 
spectra of all crude materials and purified products served as primary evidence against epimerization 
under the basic ring opening conditions. In addition, representative ring-opening product ent-6l was 
prepared and was found to have a specific rotation equal and opposite to 6l (Table 2, insert). The 
optical purities of 6l and ent-6l were further confirmed by analytical chiral HPLC.21 
 
A divergent reaction mechanism is proposed in Scheme 2 to account for the formation of 6 and side 
product 7. Initially, nucleophilic addition of the organocuprate produces common intermediate 8, which 
can either be attacked by a second equivalent of the carbanion to give the fully ring-opened diamine 7 
(blue arrows, intermolecular pathway) or undergo an intramolecular N-acylation22,23 to produce bicyclic 
intermediate 9 (red arrows, intramolecular pathway).24 Subsequent addition of a second equivalent of 
the organocuprate to 9 ultimately produces imidazolidinone 6. This mechanistic proposal is consistent 
with our earlier data in that the resultant ratio of 6:7 was found to increase with higher dilution and 
lesser equivalents of the carbanion; conditions which would be expected to favor the intramolecular 
pathway. Furthermore, the propensity for secondary alkyl and cyclic Grignard reagents to produce 
greater quantities of 7 can be rationalized by the higher reactivity of their derived organocuprates 
towards 8, as the rate of competing cyclization to 9 is presumably independent of the pendant R group. 
Notably, the possibility of an alternative entry (or additional contribution) to 6 via cyclization of 
intermediate 10 can be ruled out on the basis that an extended stirring time did not alter the final 
product ratio, although this mode of ring closure has been reported for the lithium dianion of an aryl 
ortho-dicarbamate.25 
 
Scheme 2. Proposed Reaction Mechanisma 
 
a (MgX)+ counterions are omitted for clarity. 
 
In an attempt to characterize the reaction products of mono-carbanion addition, we performed an 
experiment with a limiting amount of i-PrMgCl and maintained the temperature below −10 °C (Scheme 
3). Interestingly, TLC and NMR analyses of the crude mixture did not reveal any new reaction 
products; only the previously characterized di-addition products 6b and 7b were present, in addition to 
unreacted 5 as the major component. The absence of 11 was not overly surprising, given that there are 
presumably two modes for the consumption of its anionic precursor 8 (see Scheme 2), but the lack of 
observation of 9 is more difficult to rationalize. Essentially, if 9 is formed during the ring opening 
process, its absence in the crude mixture suggests either its instability to the aqueous workup 
conditions,26 or a significantly greater reactivity to ring opening than 5, thereby being consumed more 
rapidly by the available carbanion. In line with the latter, a number of related aziridine-fused 
imidazolidinones27 and oxazolidinones27 have been shown to undergo facile and regioselective 
nucleophilic ring opening at the terminal methylene position, including by organocuprates.26b,c,27b. 
Scheme 3. Reaction of 5 with Limiting i-PrMgCl 
i-PrMgCl (1.1 equiv)
CuBr SMe2 (15 mol %)

















In summary, we have developed a new, enantiospecific route to 2-imidazolidinones via the ring 
opening of Boc-protected 2,2'-biaziridine with Grignard reagents. As demonstrated, this method has the 
potential to access a diverse range of enantiopure 2-imidazolidinones in a single step from a common, 
easily prepared chiral-pool precursor. This approach can be considered as a variant of the classical 
‘vicinal diamine + carbonyl source’ imidazolidinone synthesis, whereby in this case the latent diamine 
is embedded in the biaziridine. Further elaboration of the products prepared herein towards new 
catalysts and medicinally relevant materials can be readily envisioned, taking advantage of the 
embedded halogen, alkoxy and olefin moieties, as well as the numerous methods available for N-
functionalization of 2-imidazolidinones.28  
 
Experimental Section 
General Methods and Materials. All reactions were carried out in standard laboratory glassware with 
magnetic stirring under N2. Thin layer chromatography (TLC) was performed on aluminum-backed 
0.20 mm silica gel plates. Visualization was accomplished with UV light or a solution of 
phosphomolybdic acid in ethanol. Flash chromatography was performed under positive air pressure 
using Silica Gel 60 of 230−400 mesh (40−63 m). Melting points (mp) are uncorrected. Optical 
Rotations were measured in CH2Cl2 with a path length of 1.0 dm ( = 589 nm). Proton and carbon 
magnetic resonance spectra (1H NMR and 13C NMR) were recorded at 300 MHz, or at 500 MHz, as 
specified. Spectra were aquired in CDCl3 and are reported relative to tetramethylsilane (
1H:  = 0.00 
ppm) and solvent resonance (13C:  = 77.0 ppm). 1H NMR data are reported as follows: chemical shift, 
multiplicity (abbreviations: s = singlet, bs = broad singlet, d = doublet, bd = broad doublet, dd = 
doublet of doublets, t = triplet, q = quartet, m = multiplet), coupling constant (Hz) and integration. High 
resolution mass spectrometry (HRMS) was performed on a QTOF ESI Spectrometer or on a TOF EI 
Spectrometer. 
 
Anhydrous tetrahydrofuran was obtained commercially. (2S,2'S)-1,1'-Di-(tert-butoxycarbonyl)-2,2'-
biaziridine 5 and its (R,R)-enantiomer (ent-5) were prepared from D- and L-tartaric acid, respectively, 
according to a published procedure.12 Notably, 5 is a bench-stable solid, that can be stored indefinitely 
at ambient temperature without decomposition. 2-Bromophenylmagnesium chloride was prepared from 
2-bromoiodobenzene via I/Mg exchange with i-PrMgCl.29 3-Chlorophenylmagnesium chloride was 
prepared from 1-bromo-3-chlorobenzene via Br/Mg exchange with i-PrMgCl·LiCl.30 Other Grignard 
reagents were obtained commercially or prepared from freshly acid-washed Mg turnings. All other 
reagents and solvents were obtained reagent grade from commercial sources and used as received. 
 
General Procedure for the Ring Opening of Biaziridine 5 with Grignard Reagents. To a 
suspension of 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10−15 mol % wrt the Grignard reagent) in THF 
at −40 °C (liquid N2/MeCN slush bath) was added a Grignard reagent (2.4−3.6 equiv) in THF (total 
volume of THF = 5.6 mL; individual proportions vary depending on the Grignard concentration). The 
resulting solution was allowed to warm to rt with stirring over 16 h. The mixture was quenched with 
saturated NH4Cl (2 mL), diluted with brine (10 mL) and extracted with EtOAc (20 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was analyzed by 
1H 
NMR spectroscopy to determine the product ratio, before being subjected to flash chromatography to 
isolate the desired imidazolidinone. 
 
(4S,5S)-2,7-Dimethyl-4,5-di(N-tert-butoxycarbonylamino)octane (7b) and (4S,5S)-4,5-Diisobutyl-1-
tert-butoxycarbonyl-2-imidazolidinone (6b). The title compounds were prepared according to the 
general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 mmol) in THF (5.4 
mL) and a solution of i-PrMgCl (1.8 M in THF, 0.19 mL, 0.34 mmol). Flash chromatography (2.4 g 
silica, 5% EtOAc/hexanes) gave 7b (13.5 mg, 26%) as a white solid. mp 146−147 °C; TLC (15% 
EtOAc/pet ether) RF = 0.71; 
21]α[ D  −65.9 (c 2.77, CH2Cl2); 
1H NMR (300 MHz, CDCl3, major rotamer 
only) δ 4.45 (bd, J = 9.1 Hz, 2H), 3.63–3.46 (m, 2H), 1.74–1.61 (m, 2H), 1.43 (s, 18H), 1.36–1.22 (m, 
4H), 0.94–0.88 (m, 12H); 13C NMR (75 MHz, CDCl3) δ 156.3, 79.0, 52.9, 42.4, 28.4, 24.9, 23.4, 21.9; 
IR (neat) v 3351, 2949, 1685, 1534, 1362, 1291, 1179, 1011 cm-1; HRMS (EI) calcd for C20H40N2O4 
372.2988 [M]·+, found 372.3001. Further elution (5% to 20% EtOAc/hexanes) gave 6b (20.0 mg, 48%) 
as a colorless gum. TLC (30% EtOAc/pet ether) RF = 0.32; 
21]α[ D  −5.4 (c 4.23, CH2Cl2); 
1H NMR (300 
MHz, CDCl3) δ 6.33 (bs, 1H), 3.77 (t, J = 7.2 Hz, 1H), 3.25 (t, J = 7.2 Hz, 1H), 1.53 (s, 9H), 1.74−1.32 
(m, 5H), 1.30−1.22 (m, 1H), 0.97−0.91 (m, 12H); 13C NMR (75 MHz, CDCl3) δ 155.7, 150.4, 82.0, 
59.5, 52.1, 45.4, 42.4, 28.1, 24.3, 24.2, 23.9, 23.0, 22.0, 21.5; IR (neat) v 3289, 2952, 2866, 1787, 
1711, 1370, 1336, 1254, 1164 , 1131, 1102, 778 cm-1; HRMS (EI) calcd for C16H30N2O3 298.2256 
[M]·+, found 298.2259. 
 
(4S,5S)-4,5-Di(cyclohexylmethyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6c). This was prepared 
according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 
mmol) in THF (5.2 mL) and a solution of cyclohexylmagnesium chloride (1.84 M in THF, 0.20 mL, 
0.37 mmol). Flash chromatography (2.0 g silica, 20% EtOAc/hexanes) gave 6c (24.3 mg, 46%) as an 
amorphous solid. TLC (20% EtOAc/pet ether) RF = 0.14; = −2.2 (c 1.20, CH2Cl2); 
1H NMR (500 
MHz, CDCl3) δ 5.93 (s, 1H), 3.81 (d, J = 9.6 Hz, 1H), 3.28 (t, J = 7.0 Hz, 1H), 1.86–1.38 (m, 21H), 
1.38–1.11 (m, 9H), 1.08–0.87 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 155.4, 150.4, 82.0, 58.9, 51.5, 
43.9, 41.0, 34.4, 34.0, 33.9, 33.5, 33.0, 32.5, 28.2, 26.4, 26.3, 26.10, 26.07; IR (neat) v 3284, 2921, 
2346, 1776, 1744, 1701, 1340, 1250, 1157, 857, 774, 733 cm-1; HRMS (ESI) calcd for C22H38N2NaO3 
401.2780 [M+Na]+, found 401.2765. 
 
(4S,5S)-4,5-Di(cyclopropylmethyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6d). This was prepared 
according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 
mmol) in THF (4.55 mL) and a solution of cyclopropylmagnesium bromide (0.5 M in THF, 0.85 mL, 
0.42 mmol). Flash chromatography (2.0 g silica, 30% EtOAc/hexanes) gave 6d (26.2 mg, 63%) as an 
amorphous solid. TLC (40% EtOAc/pet ether) RF = 0.40; = −6.8 (c 1.20, CH2Cl2); 
1H NMR (500 
MHz, CDCl3) δ 6.05 (s, 1H), 3.94 (d, J = 9.0 Hz, 1H), 3.49 (t, J = 5.7 Hz, 1H), 1.79–1.70 (m, 2H), 
1.61–1.47 (m, 10H), 1.40–1.30 (m, 1H), 0.76–0.64 (m, 2H), 0.58–0.41 (m, 4H), 0.20–0.08 (m, 4H); 13C 
25]α[ D
25]α[ D
NMR (125 MHz, CDCl3) δ 155.6, 150.4, 82.0, 60.6, 54.1, 41.0, 38.0, 28.1, 6.8, 6.3, 5.0, 4.4, 3.9, 3.5; 
IR (neat) v 3303, 2987, 2335, 1772, 1701, 1343, 1251, 1162, 1018, 855, 824, 775, 756 cm-1; HRMS 
(ESI) calcd for C16H26N2NaO3 317.1841 [M+Na]
+, found 317.1826. 
 
(4S,5S)-4,5-Diethyl-1-tert-butoxycarbonyl-2-imidazolidinone (6e). This was prepared according to the 
general procedure using 5 (41.5 mg, 0.15 mmol) and CuBr·SMe2 (14.2 mg, 0.069 mmol) in THF (5.58 
mL) and a solution of methylmagnesium chloride (1.8 M in THF, 0.26 mL, 0.46 mmol). Flash 
chromatography (2.0 g silica, 30% EtOAc/hexanes) gave 6e (21.0 mg, 59%) as a pale yellow gum. 
TLC (40% EtOAc/pet ether) RF = 0.37; = −2.0 (c 1.05, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 
5.63 (bs, 1H), 3.73 (d, J = 8.3 Hz, 1H), 3.14 (t, J = 6.0 Hz, 1H), 1.84–1.57 (m, 4H), 1.53 (s, 9H), 0.98–
0.88 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 155.8, 150.5, 82.1, 61.2, 54.6, 29.2, 28.1, 26.4, 9.1, 8.5; IR 
(neat) v 2968, 1774, 1738, 1702, 1344, 1253, 1161, 1102, 855, 775, 757 cm-1; HRMS (ESI) calcd for 
C12H22N2NaO3 265.1528 [M+Na]
+, found 265.1530. 
 
(4S,5S)-4,5-Di(4-pentenyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6f). This was prepared according 
to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 mmol) in THF 
(4.6 mL) and a solution of but-3-en-1-ylmagnesium bromide (0.44 M in THF, 0.83 mL, 0.37 mmol). 
Flash chromatography (2.0 g silica, 20% EtOAc/hexanes) gave 6f (31.6 mg, 68%) as an amorphous 
solid. TLC (20% EtOAc/pet ether) RF = 0.10; = −2.6 (c 1.60, CH2Cl2); 
1H NMR (500 MHz, 
CDCl3) δ 6.49 (bs, 1H), 5.84–5.71 (m, 2H), 5.08–4.92 (m, 4H), 3.75 (d, J = 8.5 Hz, 1H), 3.19 (t, J = 6.5 
Hz, 1H), 2.13–2.02 (m, 4H), 1.76–1.61 (m, 2H), 1.59–1.31 (m, 15H); 13C NMR (125 MHz, CDCl3) δ 
155.6, 150.5, 137.93, 137.86, 115.2, 115.1, 82.1, 60.4, 53.7, 35.8, 33.4, 33.3, 33.0, 28.1, 24.1, 23.7; IR 
(neat) v 3309, 2931, 2358, 1773, 1700, 1340, 1249, 1157, 909, 855, 775, 756, 638 cm-1; HRMS (ESI) 
calcd for C18H30N2NaO3 345.2154 [M+Na]
+, found 345.2142. 
 
(4S,5S)-4,5-Di(4-benzyloxybutyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6g). This was prepared 
according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 
mmol) in THF (3.9 mL) and a solution of 3-benzyloxypropylmagnesium bromide (0.24 M in THF, 1.53 
mL, 0.37 mmol). Flash chromatography (2.0 g silica, 30% EtOAc/hexanes) gave 6g (54.3 mg, 76%) as 
an amorphous solid. TLC (40% EtOAc/pet ether) RF = 0.23; = −3.8 (c 2.70, CH2Cl2); 
1H NMR 
(500 MHz, CDCl3) δ 7.38–7.24 (m, 10H), 5.65 (bs, 1H), 4.48 (s, 4H), 3.75 (d, J = 8.7 Hz, 1H), 3.46 (q, 




CDCl3) δ 155.4, 150.4, 138.40, 138.36, 128.31, 128.30, 127.60, 127.56, 127.51, 127.48, 82.1, 72.90, 
72.87, 69.8, 69.7, 60.4, 53.6, 36.2, 33.3, 29.5, 29.4, 28.1, 21.6, 21.1; IR (neat) v 3929, 2858, 2360, 
1773, 1696, 1457, 1340, 1249, 1098, 855, 736, 697 cm-1; HRMS (ESI) calcd for C30H42N2NaO5 
533.2991 [M+Na]+, found 533.3013. 
 
(4S,5S)-4,5-Di(2-(2-bromophenyl)ethyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6h). This was 
prepared according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 
0.053 mmol) in THF (3.8 mL) and a solution of 2-bromobenzylmagnesium bromide (0.25 M in Et2O, 
1.60 mL, 0.40 mmol). Flash chromatography (2.0 g silica, 30% EtOAc/hexanes) gave 6h (47.4 mg, 
61%) as an amorphous solid. TLC (30% EtOAc/pet ether) RF = 0.21; = −15.1 (c 2.35, CH2Cl2); 
1H 
NMR (500 MHz, CDCl3) δ 7.52 (t, J = 8.9 Hz, 2H), 7.29–7.02 (m, 6H), 6.77 (bs, 1H), 3.99–3.93 (m, 
1H), 3.44 (t, J = 5.7 Hz, 1H), 2.85–2.68 (m, 4H), 2.06–1.96 (m, 2H), 1.94–1.81 (m, 2H), 1.50 (s, 9H); 
13C NMR (125 MHz, CDCl3, one doubly degenerate ArC) δ 155.7, 150.2, 140.0, 139.9, 132.91, 132.88, 
130.4, 130.2, 128.0, 127.9, 127.7, 127.6, 124.2, 82.3, 60.0, 53.0, 36.5, 33.7, 31.7, 31.2, 28.1; IR (neat) 





(4S,5S)-4,5-Di(2-propenyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6i). This was prepared according 
to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (14.2 mg, 0.069 mmol) in THF 
(5.34 mL) and a solution of vinylmagnesium chloride (1.6 M in THF, 0.29 mL, 0.46 mmol). Flash 
chromatography (2.0 g silica, 30% EtOAc/hexanes) gave 6i (21.5 mg, 57%) as a pale yellow gum. TLC 
(40% EtOAc/pet ether) RF = 0.36; = −13.4 (c 0.74, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 5.84 
(bs, 1H), 5.77–5.64 (m, 2H), 5.19–5.11 (m, 4H), 3.87 (d, J = 8.4 Hz, 1H), 3.33 (t, J = 5.9 Hz, 1H), 
2.56–2.48 (m, 1H), 2.46–2.38 (m, 1H), 2.30–2.18 (m, 2H), 1.53 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 
155.3, 150.2, 132.2, 132.1, 119.41, 119.35, 82.4, 59.0, 52.0, 40.3, 37.7, 28.1; IR (neat) v 2913, 1771, 
1704, 1343, 1251, 1158, 1103, 914, 855, 774, 756, 621 cm-1; HRMS (ESI) calcd for C14H22N2NaO3 
289.1528 [M+Na]+, found 289.1516. 
 
(4S,5S)-4,5-Di(3-methyl-2-butenyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6j). This was prepared 
according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 
mmol) in THF (4.55 mL) and a solution of 2-methylprop-1-en-1-ylmagnesium bromide (0.5 M in THF, 
0.84 mL, 0.42 mmol). Flash chromatography (2.0 g silica, 20% EtOAc/hexanes) gave 6j (18.0 mg, 
25]α[ D
25]α[ D
40%) as an amorphous solid. TLC (30% EtOAc/pet ether) RF = 0.31; = −17.6 (c 0.90, CH2Cl2); 
1H 
NMR (300 MHz, CDCl3) δ 5.77 (s, 1H), 5.12–4.96 (m, 2H), 3.77 (d, J = 7.8 Hz, 1H), 3.18 (t, J = 6.4 
Hz, 1H), 2.51–2.05 (m, 4H), 1.72 (s, 6H), 1.64 (s, 3H), 1.62 (s, 3H), 1.53 (s, 9H); 13C NMR (75 MHz, 
CDCl3, one doubly degenerate CH3) δ 155.5, 150.4, 136.2, 136.0, 118.0, 117.7, 82.1, 59.8, 53.0, 34.7, 
31.7, 28.1, 25.8, 18.1, 18.0; IR (neat) v 3287, 2979, 2360, 1769, 1340, 1249, 1157, 853, 774, 756 cm-1; 
HRMS (ESI) calcd for C18H30N2NaO3 345.2154 [M+Na]
+, found 345.2147. 
 
(4S,5S)-4,5-Dibenzyl-1-tert-butoxycarbonyl-2-imidazolidinone (6k). This was prepared according to the 
general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (14.2 mg, 0.069 mmol) in THF (5.30 
mL) and a solution of phenylmagnesium chloride (1.4 M in THF, 0.33 mL, 0.46 mmol). Flash 
chromatography (2.0 g silica, 30% EtOAc/hexanes) gave 6k (31.2 mg, 60%) as an amorphous solid. 
TLC (40% EtOAc/PE) RF = 0.38; = −25.3 (c 1.12, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.33–
7.17 (m, 6H), 7.14 (d, J = 7.0 Hz, 2H), 6.92 (d, J = 7.1 Hz, 2H), 4.87 (bs, 1H), 4.13 (d, J = 10.0 Hz, 
1H), 3.46 (t, J = 6.8 Hz, 1H), 3.26 (dd, J = 13.3, 3.6 Hz, 1H), 2.71 (dd, J = 13.3, 10.0 Hz, 1H), 2.59 
(dd, J = 13.4, 8.7 Hz, 1H), 2.46 (dd, J = 13.4, 5.2 Hz, 1H), 1.58 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 
155.0, 150.1, 136.0, 135.8, 129.2, 128.9, 128.69, 128.65, 126.82, 126.79, 82.5, 60.7, 53.5, 42.0, 39.1, 
28.1; IR (neat) v 1762, 1490, 1340, 1152, 1061, 1022, 847, 748, 701 cm-1; HRMS (ESI) calcd for 
C22H26N2NaO3 389.1841 [M+Na]
+, found 389.1827. Note that ent-6k has been previously synthesized 
in nine steps from a protected L-aspartic acid derivative, although neither the specific rotation nor 13C 
NMR data was reported.15c 
 
(4S,5S)-4,5-Di(2-bromobenzyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6a). This was prepared 
according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 
mmol) in THF (3.52 mL) and a solution of 2-bromophenylmagnesium chloride (0.6 M in THF, 1.88 
mL, 1.13 mmol). Flash chromatography (2.0 g silica, 30% EtOAc/hexanes) gave 6a (44.3 mg, 60%) as 
a pale yellow gum. Spectral data for 6a was consistent with that reported previously.11 
 
(4S,5S)-4,5-Di(2-methoxybenzyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6l). This was prepared 
according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 
mmol) in THF (4.50 mL) and a solution of 2-methoxyphenylmagnesium bromide (0.46 M in THF, 0.92 
mL, 0.42 mmol). Flash chromatography (2.0 g silica, 40% EtOAc/hexanes) gave 6l (48.1 mg, 80%) as 
a white solid. mp 136−138 °C; TLC (40% EtOAc/pet ether) RF = 0.33; 
25]α[ D  −18.0 (c 0.61, CH2Cl2); 
25]α[ D
25]α[ D
1H NMR (500 MHz, CDCl3) δ 7.20–7.10 (m, 2H), 7.00 (d, J = 7.4 Hz, 1H), 6.88 (d, J = 7.4 Hz, 1H), 
6.85–6.75 (m, 2H), 6.71 (d, J = 8.2 Hz, 1H), 6.66 (d, J = 8.2 Hz, 1H), 5.26 (bs, 1H), 4.28 (dd, J = 10.1, 
4.3 Hz, 1H), 3.68 (s, 3H), 3.59 (s, 3H), 3.55 (t, J = 7.2 Hz, 1H), 3.21 (dd, J = 13.0, 4.3 Hz, 1H), 2.71 (t, 
J = 10.7 Hz, 1H), 2.62 (dd, J = 13.2, 7.2 Hz, 1H), 2.55 (dd, J = 13.2, 6.8 Hz, 1H), 1.56 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 157.6, 157.3, 155.3, 150.4, 131.4, 130.9, 128.1, 128.0, 124.6, 124.5, 120.4, 
120.3, 110.21, 110.18, 81.9, 59.0, 55.0, 54.9, 51.6, 37.1, 34.1, 28.2; IR (neat) v 2921, 1776, 1492, 




(4R,5R)-4,5-Di(2-methoxybenzyl)-1-tert-butoxycarbonyl-2-imidazolidinone (ent-6l). This was prepared 
according to the general procedure using ent-5 (40.6 mg, 0.14 mmol) and CuBr·SMe2 (14.2 mg, 0.069 
mmol) in THF (4.78 mL) and a solution of 2-methoxyphenylmagnesium bromide (0.46 M in THF, 0.92 
mL, 0.42 mmol). Flash chromatography (2.0 g silica, 30% EtOAc/hexanes) gave ent-6l (51.3 mg, 84%) 
as a white solid. Spectral data for ent-6l was consistent with that reported above for 6l. 25]α[ D  +18.3 (c 
2.08, CH2Cl2). 
 
(4S,5S)-4,5-Di(3,5-dimethoxybenzyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6m). This was prepared 
according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 
mmol) in THF (4.4 mL) and a solution of 3,5-dimethoxyphenylmagnesium bromide (0.49 M in THF, 
1.0 mL, 0.49 mmol). Flash chromatography (2.0 g silica, 40% EtOAc/hexanes) gave 6m (40.8 mg, 
60%) as an amorphous solid. TLC (50% EtOAc/pet ether) RF = 0.35; = −15.0 (c 2.00, CH2Cl2); 
1H 
NMR (500 MHz, CDCl3) δ 6.30 (s, 1H), 6.25 (s, 1H), 6.24 (s, 2H), 6.06 (s, 2H), 5.17 (bs, 1H), 4.08 (d, 
J = 9.5 Hz, 1H), 3.75 (s, 6H), 3.72 (s, 6H), 3.47 (t, J = 7.2 Hz, 1H), 3.19 (dd, J = 13.2, 3.4 Hz, 1H), 
2.62–2.52 (m, 2H), 2.41 (dd, J = 13.3, 6.1 Hz, 1H), 1.58 (s, 9H); 13C NMR (125 MHz, CDCl3, two 
doubly degenerate ArC’s) δ 160.9, 154.7, 150.2, 138.2, 138.1, 107.2, 106.8, 98.8, 82.6, 60.8, 55.2, 
55.1, 53.7, 42.6, 39.5, 28.2; IR (neat) v 1772, 1607, 1595, 1458, 1429, 1340, 1293, 1205, 1148, 1064, 
831, 691 cm-1; HRMS (ESI) calcd for C26H34N2NaO7 509.2264 [M+Na]
+, found 509.2265. 
 
(4S,5S)-4,5-Di(3,4-methylenedioxybenzyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6n). This was 
prepared according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 
0.053 mmol) in THF (4.4 mL) and a solution of 3,4-(methylenedioxy)phenylmagnesium bromide (0.42 
M in THF, 1.0 mL, 0.42 mmol). Flash chromatography (2.0 g silica, 40% EtOAc/hexanes) gave 6n 
25]α[ D
(44.5 mg, 70%) as an amorphous solid. TLC (50% EtOAc/pet ether) RF = 0.36; = +1.8 (c 0.80, 
CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 6.66 (d, J = 7.7 Hz, 1H), 6.62 (d, J = 7.8 Hz, 1H), 6.50–6.45 
(m, 2H), 6.38 (d, J = 7.9 Hz, 1H), 6.34 (s, 1H), 5.97–5.89 (m, 4H), 5.78 (bs, 1H), 3.99 (d, J = 9.7 Hz, 
1H), 3.40 (t, J = 7.1 Hz, 1H), 3.12 (dd, J = 13.3, 3.3 Hz, 1H), 2.60 (dd, J = 13.5, 6.5 Hz, 1H), 2.52 (dd, 
J = 13.2, 10.4 Hz, 1H), 2.40 (dd, J = 13.5, 7.5 Hz, 1H), 1.58 (s, 9H); 13C NMR (125 MHz, CDCl3, one 
doubly degenerate ArC) δ 154.9, 150.2, 147.74, 147.69, 146.4, 129.6, 129.4, 122.3, 122.1, 109.2, 
109.0, 108.20, 108.18, 101.01, 100.99, 82.6, 60.6, 53.7, 41.8, 38.8, 28.2; IR (neat) v 3285, 2331, 1769, 
1490, 1341, 1242, 1188, 1037, 928, 854, 813, 773, 735 cm-1; HRMS (ESI) calcd for C24H26N2NaO7 
477.1638 [M+Na]+, found 477.1649. 
 
(4S,5S)-4,5-Di(2-methylbenzyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6o). This was prepared 
according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 
mmol) in THF (4.9 mL) and a solution of o-tolylmagnesium chloride (1.0 M in THF, 0.47 mL, 0.47 
mmol). Flash chromatography (2.0 g silica, 20% EtOAc/hexanes) gave 6o (30.7 mg, 55%) as an 
amorphous solid. TLC (20% EtOAc/pet ether) RF = 0.10; = −14.7 (c 1.55, CH2Cl2); 
1H NMR (300 
MHz, CDCl3) δ 7.16–6.92 (m, 7H), 6.76 (d, J = 7.4 Hz, 1H), 6.28 (bs, 1H), 4.14 (dd, J = 10.8, 4.5 Hz, 
1H), 3.46 (t, J = 7.4 Hz, 1H), 3.27 (dd, J = 13.4, 4.5 Hz, 1H), 2.80–2.44 (m, 3H), 2.12 (s, 3H), 1.91 (s, 
3H), 1.55 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 155.4, 150.3, 136.5, 136.1, 134.1, 134.0, 130.52, 
130.48, 130.45, 129.6, 126.9, 126.8, 126.0, 125.9, 82.5, 58.3, 51.5, 39.0, 36.6, 28.1, 19.2, 18.9; IR 
(neat) v 3298, 2331, 1772, 1700, 1456, 1340, 1243, 1151, 854, 741 cm-1; HRMS (ESI) calcd for 
C24H30N2NaO3 417.2154 [M+Na]
+, found 417.2145. 
 
(4S,5S)-4,5-Di(3-chlorobenzyl)-1-tert-butoxycarbonyl-2-imidazolidinone (6p). This was prepared 
according to the general procedure using 5 (40.0 mg, 0.14 mmol) and CuBr·SMe2 (10.8 mg, 0.053 
mmol) in THF (4.6 mL) and a solution of 3-chlorophenylmagnesium chloride (0.64 M in THF, 0.80 
mL, 0.51 mmol). Flash chromatography (two iterations were required: 2.0 g silica, 25% 
EtOAc/hexanes) gave 6p (22.4 mg, 37%) as a colorless gum. TLC (30% EtOAc/pet ether) RF = 0.19; 
= −8.0 (c 0.38, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.22–7.10 (m, 4H), 7.03 (s, 1H), 6.93 (d, 
J = 6.9 Hz, 1H), 6.88 (s, 1H), 6.80 (d, J = 7.2 Hz, 1H), 5.69 (bs, 1H), 4.04 (d, J = 8.4 Hz, 1H), 3.42 (t, J 
= 7.0 Hz, 1H), 3.19 (dd, J = 13.2, 3.6 Hz, 1H), 2.70–2.59 (m, 2H), 2.48 (dd, J = 13.5, 7.0 Hz, 1H), 1.58 
(s, 9H); 13C NMR (125 MHz, CDCl3, two doubly degenerate ArC’s) δ 154.6, 150.1, 137.8, 137.5, 




v 3302, 2328, 1762, 1574, 1424, 1337, 1198, 1148, 1050, 786, 689 cm-1; HRMS (ESI) calcd for 
C22H24Cl2N2NaO3 457.1062 [M+Na]
+, found 457.1079. 
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